Go here to read the rest:
Colossal Creates the Colossal Woolly Mouse, Showcasing Breakthroughs in Multiplex Genome Editing and Trait Engineering on the Path to a Mammoth -...
Biotech company hoping to revive woolly mammoth, creates woolly mouse: Study Straight Arrow News
Link:
Biotech company hoping to revive woolly mammoth, creates woolly mouse: Study - Straight Arrow News
'We didn't know they were going to be this cute': Scientists unveil genetically engineered 'woolly mice' Livescience.com
Follow this link:
'We didn't know they were going to be this cute': Scientists unveil genetically engineered 'woolly mice' - Livescience.com
Biotech Company Creates 'Woolly Mouse' as a Step in Its Quest to Resurrect Woolly Mammoths Through Gene Editing Smithsonian Magazine
View original post here:
Biotech Company Creates 'Woolly Mouse' as a Step in Its Quest to Resurrect Woolly Mammoths Through Gene Editing - Smithsonian Magazine
Turning back the aging clock: Billions of dollars are probably being wasted on genetic manipulation techniques that likely wont work Genetic Literacy Project
Read the original:
Turning back the aging clock: Billions of dollars are probably being wasted on genetic manipulation techniques that likely wont work - Genetic...
Genetically altered mouse to pave way for resurrection of wolly mammoth? Hindustan Times
Read more:
Genetically altered mouse to pave way for resurrection of wolly mammoth? - Hindustan Times
These Genetically Engineered Mice Have Thick Woolly Mammoth Hair ExtremeTech
Go here to read the rest:
These Genetically Engineered Mice Have Thick Woolly Mammoth Hair - ExtremeTech
How scientists created woolly mice as part of their quest to bring back the woolly mammoth The Indian Express
Go here to read the rest:
How scientists created woolly mice as part of their quest to bring back the woolly mammoth - The Indian Express
Woolly mouse unveiled by firm hoping to bring more extinct animals back to life The National
Originally posted here:
Woolly mouse unveiled by firm hoping to bring more extinct animals back to life - The National
OF WOOLLY MICE AND MAMMOTHS Particle
Visit link:
OF WOOLLY MICE AND MAMMOTHS - Particle
A Woolly What? Brownstone Research
Visit link:
A Woolly What? - Brownstone Research
NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options. NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options.
Extends cash runway well into mid-2026; no new/replacement warrants issued Extends cash runway well into mid-2026; no new/replacement warrants issued
See the original post:
Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2024 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 5, 2025.
BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer, will present recently announced data from the company’s Expanded Access Program (EAP) evaluating INZ-701 in infants and children with ENPP1 Deficiency at the CHOP Cardiology Annual Meeting, held February 19-23, 2025, in Orlando, Florida.
Read the original here:
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
Go here to see the original:
Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call
MIAMI, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report full-year 2024 financial results and provide a business update on Friday, February 28, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.
The rest is here:
Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025
ORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Biostax Corp (OTC Pink: BIOX) ("Biostax" or "the Company"), a biopharmaceutical company focused on developing innovative immune restoration therapies, today announced its Board of Directors has approved and the Company intends to proceed with the voluntary delisting of its common stock from the OTC Pink marketplace. This strategic decision follows strong shareholder support, with 76.4% voting in favor of the delisting through a Joint Written Consent.
More here:
Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration
MORRIS PLAINS, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ensho Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases, announced today the presentation of additional supportive data for NSHO-101 (also known as EA1080) as a potential once-daily treatment for inflammatory bowel disease (IBD) at the 20th congress of the European Crohn’s and Colitis Organisation (ECCO 2025) meeting being held in Berlin, Germany.
See the article here:
Ensho Therapeutics Announces Presentation of Data Highlighting NSHO-101 as a Once-Daily Oral Agent for the Potential Treatment of Inflammatory Bowel...
Ipsen S.A. - 2024 Consolidated Financial Statements
View post:
Ipsen S.A. publishes its 2024 consolidated financial statements